During the past decade, Central New York Research Corporation conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Central New York Research Corporation" are "Parkinson's Disease" (1 trials) and "Recurrent C. Difficile Infection" (1 trials). Many other conditions were trialed in "Central New York Research Corporation" in a lesser frequency.

Most popular intervention types in "Central New York Research Corporation" are "Biological" (1 trials), "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "CP101" (1 trials), "Carbidopa/levodopa/entacapone" (1 trials), "Immediate release carbidopa/levodopa" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Central New York Research Corporation" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Central New York Research Corporation". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Central New York Research Corporation, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Central New York Research Corporation, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".